For GSK126, here is the recommended preparation method for your experiment:

1. 30% PEG300 + 70% (20% SBE-β-CD in Saline) (Suspended) 1.67 mg/mL ;

2. (ultrasonic) 1% CMC/0.5% Tween-80 in Saline water (Suspended) 10 mg/mL (ultrasonic);

Uniform suspension is suitable for intraperitoneal or gavage administration. Note: If you prepare a uniform suspension, do not filter before administration, as filtration removes drug particles.

Criteria for Uniform Suspension:

The suspension should show no obvious phase separation, sedimentation, or particle aggregation and should appear evenly dispersed. After gentle shaking, the appearance should be uniform without visible clumps.

The answer to this question comes from MCE Technical Support.

[email protected]

To prepare GSK126 for in vivo dosing in BALB/c nude mice xenograft experiments, follow this protocol: First, dissolve GSK126 powder in 10% DMSO, then mix with 40% PEG-300, and finally dilute with 50% sterile PBS or saline for optimal solubility and biocompatibility. Filter the solution through a 0.22 µm filter for sterilization. For administration, either intraperitoneal (IP) injection or oral gavage (PO) can be used, with IP being more common for GSK126. The typical dosage ranges from 50–200 mg/kg/day, with 50 mg/kg IP being a frequently used dose in xenograft studies. Prepare the dosing solution fresh before each administration, though aliquots can be stored at –20°C for short-term use with minimal freeze-thaw cycles. Always include a vehicle control group treated with the same solvent mixture (10% DMSO + 40% PEG-300 + 50% PBS). Monitor tumor growth regularly and validate treatment efficacy by assessing H3K27me3 reduction via IHC. This formulation is based on established protocols from literature, including studies demonstrating GSK126's effectiveness in xenograft models. Adjustments to dose or schedule may be needed depending on specific experimental conditions or observed toxicity.